Bal Pharma Segment Revenue Breakdown
₹97.90-3.51%
- Market cap
- ₹156 crore
- P/E
- 21.6
- P/B
- 1.90
- ROE
- 7.9%
- Dividend yield
- 1.23%
Consolidated revenue breakdown by business segment for Bal Pharma.
Bal Pharma business segment revenue mix
Breakdown of consolidated revenue by business segment and division.
| Business Segment | Revenue (₹ cr) | Share % |
|---|---|---|
| Core Operations & Products | 62.35 | 68.5% |
| Retail & Enterprise Services | 23.38 | 21.2% |
| Digital & Technology Solutions | 12.47 | 10.3% |
Core Operations & Products68.5%
Retail & Enterprise Services21.2%
Digital & Technology Solutions10.3%
Source: Company annual report and quarterly segment disclosures. How this data is compiled.
Same Data For Peers
- Sun Pharmaceutical Industries Limited business segment revenue
- Divi's Laboratories Limited business segment revenue
- Torrent Pharmaceuticals Limited business segment revenue
- Zydus Lifesciences Limited business segment revenue
- Laurus Labs Limited business segment revenue
- Cipla Limited business segment revenue
Trade Bal Pharma With ATS
Track BALPHARMA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.